Recent developments in federal cannabis policy center on the DEA's April 2026 order, which immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving recreational and unlicensed marijuana in Schedule I. This followed a December 2025 executive order directing expedited rulemaking. An expedited administrative hearing on broader rescheduling from Schedule I to Schedule III began June 29, 2026, and concluded by July 15, with selected participants largely opposing full reclassification. Post-hearing administrative steps, potential litigation over participant selection or procedural issues, and any final rule issuance now shape timelines. Trader consensus on prediction markets reflects uncertainty around these procedural hurdles and the pace of agency action.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया$796,389 वॉल्यूम
30 सितंबर
14%
31 दिसंबर
24%
$796,389 वॉल्यूम
30 सितंबर
14%
31 दिसंबर
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
बाज़ार खुला: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent developments in federal cannabis policy center on the DEA's April 2026 order, which immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while leaving recreational and unlicensed marijuana in Schedule I. This followed a December 2025 executive order directing expedited rulemaking. An expedited administrative hearing on broader rescheduling from Schedule I to Schedule III began June 29, 2026, and concluded by July 15, with selected participants largely opposing full reclassification. Post-hearing administrative steps, potential litigation over participant selection or procedural issues, and any final rule issuance now shape timelines. Trader consensus on prediction markets reflects uncertainty around these procedural hurdles and the pace of agency action.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया



बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न